VarMap Pan-cancer NGS Panel

About NuProbe

NuProbe is a privately held, US-based company founded in 2016 with a mission to improve the analytical sensitivity of DNA biomarker detection for cancer research and diagnostics. Its core technology platform includes Blocker Displacement Amplification (BDA) for rare allele enrichment on PCR/digital PCR and Quantitative Amplicon Sequencing (QASeq) for highly multiplexed, UMI-based NGS assays. The company has secured a significant $50M funding round, entered a key licensing agreement with Bio-Rad, and operates with a dual business model of developing research-use assays and providing custom assay development services to biopharma. NuProbe is positioned to address the growing need for sensitive liquid biopsy and tissue-based testing in oncology.

Therapeutic Areas

Other Cancer Drugs